Retrospective Analysis of Hepatitis C Cure Rates in Family Medicine Clinic

Date Added
May 15th, 2019
PRO Number
Pro00088552
Researcher
Morgan Rhodes

List of Studies

Keywords
Infectious Diseases
Summary

Hepatitis C is the most common form of hepatitis in the United States. With the prevalence on the rise, it is important to consider utilizing more accessible healthcare providers to provide patient care for these patients. Due to the evolution of hepatitis C medications and the cure rates proving almost 100% cure, we believe that utilizing these providers is an appropriate option for care.

Caring for patients with hepatitis C has been integrated into the Palmetto Health-USC Family Medicine resident curriculum since 2017 to help residents gain exposure to treating the disease during residency. To date, the treatment success rate for resident primary care providers has not been studied.

Institution
Palmetto
Recruitment Contact
Morgan Rhodes
8034342072
morgan.adams@uscmed.sc.edu

A Multi-Institutional Neurocognitive Discovery Study (MINDS) in Adult Congenital Heart Disease (ACHD): MINDS-ACHD

Date Added
January 16th, 2020
PRO Number
Pro00085138
Researcher
John Rhodes

List of Studies


Keywords
Heart
Summary

This is a multicenter cross-sectional pilot analysis of objective and subjective neurocognitive deficits (NCD) and genetics in the Adults with Congenital Heart Disease (ACHD) population ages 18-30 years with moderate and severe complexity of congenital heart disease (CHD).

The expectation is that studying NCD in ACHD will help to guide access to resources and appropriate medical care for these patients. This research should facilitate the use of targeted interventions in the ACHD population with NCD to enhance both long term quality of care and quality of life (QOL).

Institution
MUSC
Recruitment Contact
Kalyan Chundru
843-792-1213
choudhar@musc.edu

GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

Date Added
February 25th, 2020
PRO Number
Pro00095864
Researcher
John Rhodes

List of Studies


Keywords
Heart
Summary

REDUCE study is researching the safety and effectiveness of GOREĀ® CARDIOFORM Septal Occluder (GSO ) device in closing the patent foramen ovale (PFO) in patients who have a PFO and had a stroke of unknown origin (cryptogenic stroke). This device has been approved by the United States Food and Drug Administration for this indication.

A PFO is a common opening in the wall (septum) between the two upper chambers (the right and left atria) of the heart. In most cases, this opening closes around the time of birth. If the opening remains after birth, it can allow the blood to mix in the two upper chambers of the heart.

In most people, leaving the opening untreated has no negative consequences. However, in some patients who have had a stroke of unknown origin (cryptogenic stroke), the presence of a PFO may increase the risk of having another stroke if the opening is left untreated.

Institution
MUSC
Recruitment Contact
Kalyan Chundru
843-792-1213
choudhar@musc.edu

MINDS Imaging Ancillary Study

Date Added
September 1st, 2021
PRO Number
Pro00111435
Researcher
John Rhodes

List of Studies


Keywords
Heart
Summary

Adults with Cognitive Heart Disease (ACHD) now outnumber children with CHD. ACHD patients can demonstrate some neurocognitive deficits which may reduce their quality of life. The goal of this research is to determine if the mind's ability to resist damage of the brain can impact the development and neurocognitive outcomes in ACHD patients.

Institution
MUSC
Recruitment Contact
Terry Headley
843-792-4629
headleyt@musc.edu

Evaluation of the safety and efficacy of the reSept ASD Occluder to treat patients with clinically significant secundum atrial septal defect (ASCENT ASD STUDY)

Date Added
September 17th, 2021
PRO Number
Pro00111553
Researcher
John Rhodes

List of Studies


Keywords
Cardiovascular
Summary

Transcatheter closure of secundum ASD using a permanent implant is considered the standard of care for treatment of clinically significant ASD. Over the past twenty years, devices have evolved such that safety and effectiveness are equal or superior to surgical techniques while reducing the economic and psychological costs of care. Industry sources estimate that, globally, over half a million patients have received a septal occluder to treat atrial level shunts.

A key remaining drawback to all such devices is that they are permanent implants placed in a typically young population. Unlike surgical suture, which resorbs over time, all currently available septal occlusion implants are constructed with a metal framework that incorporates some amount of fabric-based material.

The reSept ASD Occluder is unique in that the framework of the implant is comprised of a bioresorbable material (PLGA) and is intended for use in patients with a clinically significant secundum ASD, who, in the judgment of their physician, require closure of the ASD and in whom a transcatheter approach is deemed appropriate.

Institution
MUSC
Recruitment Contact
Megan Bickford
843-876-3394
bickfome@musc.edu



-- OR --